Jyong Biotech Ltd.
MENSHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Jyong Biotech Ltd. focuses on Biotechnology services and products. Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States,. The $196.2M market capitalization puts MENS squarely in micro-cap range for its industry. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Market Cap
$196.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.07
EPS (Fwd)
—
ROE
—
ROA
-12.0%
Cash
$1.2M
Total Debt
$18.5M
Free CF
$4.4M
52W Change
-74.4%
Annual Financials
Cash vs Debt
Where MENS stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, MENS finished 38.16% below its 150-day moving average ($3.59) and 83.97% below its 200-day moving average ($13.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MENS overbought or oversold?
At the July 15, 2026 close, MENS's RSI(14) was 73.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, MENS has $1.2M in cash with $18.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $4.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Jyong Biotech Ltd. and its sector.